Biopress Journal of Ethnobotanical Innovations and Herbal Therapeutics Vol. 1 Issue. 2 (2026)

Mangiferin: Bridging Phytochemical Standardization and Therapeutic Translation

Monali M. Upare[1], Alkesh A. Hora[2]

[1]Assistant Professor**,** Department of Pharmaceutical Chemistry, KCT's Krishna College of Pharmacy, Karad-Pin 415539, (MS) India

[2]Student (B. Pharmacy), KCT's Krishna College of Pharmacy, Karad-Pin 415539, (MS) India

Corresponding author Email: alkeshhora@gmial.com
Doi: 10.5281/zenodo.19706770
Received: 15 February 2026
Accepted: 01 March 2026

Abstract

Mangiferin, a notable bioactive xanthone primarily isolated from Mangifera indica, has attracted considerable interest owing to its diverse pharmacological properties. This review provides a critical evaluation of mangiferin research with a focus on phytochemical standardization, which is imperative for ensuring reproducibility and facilitating clinical translation. A variety of analytical methods, such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, and ultraviolet-visible (UV-Vis) spectrophotometry, have been employed to accurately characterize and measure mangiferin, emphasizing the importance of thorough analytical approaches. Pharmacologically, mangiferin exhibits antioxidant, anti-inflammatory, antidiabetic, anticancer, and neuroprotective properties, highlighting its therapeutic promise in different disease models. Despite promising preclinical results, several challenges in translation remain, including poor bioavailability, formulation issues, and regulatory hurdles, which impede its progress to clinical use. Addressing these challenges through the creation of advanced drug delivery systems, improved standardization methods, and comprehensive regulatory frameworks is crucial to fully harness mangiferin's clinical potential.

Future investigations should prioritize the optimization of analytical standards, improvement of bioavailability, and execution of well-designed clinical trials to substantiate therapeutic efficacy. This integrative strategy will effectively bridge the gap between phytochemical standardization and therapeutic translation, establishing mangiferin as a promising candidate for pharmaceutical development.

KEYWORDS: Mangifera indica, phytochemical standardization, anti-inflammatory, antidiabetic, neuroprotective properties, analytical standards, clinical translation.

1. Introduction



Figure. 1: Mangiferin as a Translational Phytochemical: Molecular mechanisms to clinical utility

1.1 Background of Mangiferin

Mangiferin is a naturally occurring C-glucosyl xanthone predominantly isolated from *Mangifera indica*, commonly known as the mango tree, as well as from various other plant species within the Anacardiaceae family.(Al-Madhagi, 2025) This compound has been extensively studied due to its unique chemical structure and diverse pharmacological properties. Traditionally, mangiferin-containing plants have been employed in ethnomedicine across different cultures for the treatment of ailments such as inflammation, diabetes, and infections, underscoring its ethnopharmacological significance. (Akter et al., 2022; Jangra et al., 2020; Wang et al., 2022; Zivković et al., 2023)The integration of mangiferin's traditional uses with modern scientific inquiry has propelled interest in its therapeutic potential and mechanistic underpinnings.

1.2 Need for Standardization in Phytochemical Research

Phytochemical research faces considerable challenges stemming from variability in botanical sources, extraction procedures, and analytical assays, which collectively impact reproducibility and comparability of results.(Abubakar

& Haque, 2020; Etaware et al., 2025; Govindarajan et al., 2019; Sun et al., 2025) Such inconsistencies hinder the reliable assessment of bioactive compounds and impede their progression through the drug development pipeline. Standardization of phytochemicals, including mangiferin, is therefore critical to ensure consistent quality, efficacy, and safety. Establishing rigorous analytical protocols enables the accurate quantification and characterization of these compounds, facilitating their translation from bench to bedside. Mangiferin serves as a pertinent model compound for translational phytotherapy, illustrating the necessity of comprehensive standardization frameworks to bridge preclinical findings with clinical applications.(Kumar et al., 2021; Pierre et al., 2025; Tao et al., 2025)

1.3 Aim and Scope of the Review

This review is intended to offer a critical examination of the current methods used for the analytical standardization of mangiferin, assessing their strengths and weaknesses. It also aims to compile the existing pharmacological evidence that supports the therapeutic importance of mangiferin in various disease models. Lastly, the review evaluates the potential for translating mangiferin into clinical applications, highlighting significant challenges such as bioavailability and regulatory issues that need to be addressed to advance its clinical development. (Vishwakarma et al., 2025; Wang et al., 2022; Zhao et al., 2025; Zivković et al., 2023)Through this integrative approach, the review intends to highlight pathways for advancing mangiferin as a standardized phytochemical with significant pharmaceutical promise.

2. Phytochemical Profile of Mangiferin

2.1 Chemical Structure and Physicochemical Properties



Figure.2: Chemical Structure of Mangiferin

Mangiferin is a naturally occurring C-glucosyl xanthone characterized by a distinctive molecular structure comprising a xanthone core linked to a glucose moiety via a carbon–carbon bond. This unique configuration confers significant stability against enzymatic hydrolysis compared to O-glycosides. (El-Nashar et al., 2022; Tegl & Nidetzky, 2020)Mangiferin exhibits moderate polarity due to the presence of multiple hydroxyl groups, influencing its solubility profile. It is sparingly soluble in water but demonstrates enhanced solubility in polar organic solvents such as methanol and ethanol. (Liu et al., 2020; Wu et al., 2021)The compound's physicochemical stability is affected by environmental factors including pH, temperature, and light exposure, which can lead to degradation under extreme conditions.

The structural features of mangiferin are directly related to its bioactivity and formulation potential. The presence of hydroxyl groups contributes to its antioxidant capacity by facilitating free radical scavenging. Additionally, the glucose moiety enhances water solubility relative to aglycone xanthones, which is advantageous for bioavailability and formulation in aqueous-based delivery systems. The C-glycosidic bond imparts resistance to metabolic cleavage, potentially prolonging systemic circulation and therapeutic efficacy.(Morozkina et al., 2021; Vishwakarma et al., 2025)

2.2 Natural Sources and Distribution

Mangiferin is predominantly isolated from Mangifera indica, commonly known as the mango tree, where it is distributed across various plant parts including leaves, bark, fruit peel, and seed kernel. Among these, the leaves and bark are reported to contain the highest concentrations, followed by the peel and seed kernel. The compound's distribution within the plant is influenced by biosynthetic pathways and physiological roles, such as defense mechanisms against pathogens and environmental stress.(Diarra, 2014; Rossouw et al., 2024)



Figure. 3: Sources and geographical variation in Mangiferin concentration

In addition to Mangifera indica, mangiferin is also found in various other plant species from different families, albeit usually in smaller amounts. These species are often utilized in traditional medicine, highlighting the compound's widespread phytochemical importance. The levels of mangiferin can vary greatly depending on factors such as the specific part of the plant collected, its geographical location, and the conditions during harvest. The synthesis and accumulation of mangiferin are influenced by climate, soil quality, and the season in which the plant is harvested. For instance, plants grown in tropical regions with higher sunlight exposure tend to exhibit elevated mangiferin levels.(Mei et al., 2021) Similarly, harvest time and post-harvest processing methods can modulate the phytochemical profile, highlighting the necessity for standardized collection and extraction protocols to ensure consistent quality in research and formulation applications.

3. Analytical Standardization of Mangiferin

3.1 Extraction Techniques

The extraction of mangiferin encompasses both conventional and advanced methodologies to maximize yield and purity. Traditional methods like maceration and Soxhlet extraction are widely used due to their straightforward procedures and established guidelines. Maceration involves soaking plant material in solvents at room temperature for extended periods, allowing mangiferin to diffuse passively. Soxhlet extraction improves this by continuously recycling the solvent, which enhances extraction efficiency, though it often requires longer processing times and more solvent. Modern techniques such as ultrasound-assisted extraction (UAE) and microwave-assisted extraction (MAE) offer significant benefits by shortening extraction times, reducing solvent usage, and increasing yield. UAE uses ultrasonic waves to break down plant cell walls, aiding solvent penetration and compound release. MAE uses microwave radiation to quickly heat the solvent and plant material, speeding up the extraction process. Comparative studies consistently show that UAE and MAE produce higher amounts of mangiferin with greater efficiency compared to traditional methods, making them particularly suitable for large-scale or industrial use.

3.2 Analytical Methods for Identification and Quantification

Accurate identification and quantification of mangiferin are crucial for its standardization and quality control. High-performance liquid chromatography (HPLC) is the preferred analytical method due to its high sensitivity, specificity, and reproducibility, allowing effective separation of mangiferin from complex botanical matrices and precise quantification. High-performance thin-layer chromatography (HPTLC) is a cost-effective alternative for qualitative and semi-quantitative analyses, suitable for quick screening. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers enhanced selectivity and sensitivity, enabling detection at trace levels and structural analysis. Ultraviolet-visible (UV–Vis) spectroscopy is frequently applied for preliminary quantification based on characteristic absorption peaks but lacks specificity when analyzing complex mixtures.

Table 1: Comparative Extraction Techniques for Mangiferin: Yields, Strengths, and Challenges

Technique	Typical Solvents	Mangiferin Yield (mg/g)*	Strengths	Challenges
Conventional				

Maceration	Ethanol, methanol, water	5–15 pmc.ncbi.nlm.nih	Simple, low-cost; no heat degradation pmc.ncbi.nlm.nih.	24–72h duration; low efficiency; contamination risk pmc.ncbi.nlm.nih.
Soxhlet Extraction	Ethanol, methanol, chloroform	10–20 pmc.ncbi.nlm.nih	Exhaustive; solvent reuse pmc.ncbi.nlm.nih.	High solvent (15–20x); 6–48h; thermal issues pmc.ncbi.nlm.nih.
Modern/Advanced				
Ultrasound-Assisted (UAE)	Ethanol-water (44%)	25–58 pmc.ncbi.nlm.nih+1	15–60 min; 50–70% less solvent; cell disruption (200W optimal) pmc.ncbi.nlm.nih.	Equipment cost; parameter tuning pmc.ncbi.nlm.nih.
Microwave-Assisted (MAE)	Ethanol, methanol	30–50 pmc.ncbi.nlm.nih+1	5–20 min; high purity; scalable pmc.ncbi.nlm.nih.	Overheating; power control pubmed.ncbi.nlm.nih.
Supercritical Fluid (SFE)	CO_2 + ethanol	35–55 scijournals.onlinelibrary.wiley	Eco-friendly; high selectivity/purity scijournals.onlinelibrary.wiley.	Expensive high-pressure setup scijournals.onlinelibrary.wiley.
Enzyme-Assisted (EAE)	Water, buffers	20–45 pmc.ncbi.nlm.nih	Green solvents; specific hydrolysis pmc.ncbi.nlm.nih.	Enzyme optimization; cost pmc.ncbi.nlm.nih.



(MAE: Microwave-Assisted Extraction, UAE: Ultrasound-Assisted Extraction, SPE: Solid Phase Extraction, QC: Quality Control, ACN: Acetonitrile , LOD: Limit of Detection, LOQ: Loss of Quantification)

*Yields from mango leaves/peels under optimized conditions; 2–3x higher vs. convention

Figure. 4: **Schematic overview of conventional and advanced extraction techniques employed for the isolation of mangiferin from mango (*Mangifera indica*) leaves.** *The process includes pre-treatment, hydroalcoholic extraction, downstream processing, and purification to obtain high-purity Mangiferin.*

Method validation encompasses evaluation of specificity, accuracy, precision, and limits of detection (LOD) and quantification (LOQ). Specificity ensures discrimination of mangiferin from other constituents; accuracy and precision verify the reliability and reproducibility of measurements; LOD and LOQ ascertain the sensitivity thresholds for detecting minimal concentrations. Utilization of certified reference standards of mangiferin is indispensable for calibration, method validation, and ensuring inter-laboratory consistency.



Figur.5: Mangiferin Analytical standardization steps and workflow as per ICH Q2R2

3.3 Quality Control and Standardization Challenges

The quality control of formulations containing mangiferin faces numerous obstacles. Differences in plant sources, harvesting conditions, and extraction methods lead to batch-to-batch variability, which negatively impacts the mangiferin content and consistency of the products. This variability poses challenges for dose standardization and efficacy assessment. A major issue is the lack of unified pharmacopeial standards for mangiferin, hindering regulatory approval and the creation of consistent quality benchmarks. Currently, there are no universally accepted monographs or standardized protocols, leading to varied quality specifications. To overcome these issues, it is essential to develop validated analytical protocols that are robust, reproducible, and widely accepted. Establishing

standardized extraction methods, validated quantification techniques, and comprehensive quality parameters will greatly improve the reliability of mangiferin products.

Collaborative initiatives involving researchers, industry stakeholders, and regulatory authorities are essential to formulate and implement these standards to ensure effective quality control and therapeutic application.

Table 2: Overview of Standardization and Regulatory Challenges in Mangiferin Research and Development

Sr. No.	Challenge	Cause	Impact	Proposed Solution
1	Batch-to-batch variability	Differences in plant origin, harvesting conditions, and extraction techniques	Variations in mangiferin content and product uniformity	Standardize plant sourcing, harvesting protocols, and extraction methods
2	Dose standardization complexity	Resulting from inconsistent mangiferin concentration	Difficulty in ensuring consistent therapeutic efficacy	Implement validated quantification methods and robust quality control measures
3	Lack of harmonized pharmacopeial standards	Absence of universally accepted monographs or protocols	Regulatory approval challenges; inconsistent quality benchmarks	Develop and adopt standardized pharmacopeial monographs and quality criteria
4	Inconsistent quality specifications	Due to absence of standardized protocols	Reduced product reliability and consumer confidence	Establish validated analytical protocols that are reproducible and widely endorsed
5	Regulatory acceptance barriers	Variability and lack of standardized methods	Delays or hurdles in market authorization	Foster collaboration among researchers,

				industry, and regulatory bodies to formulate unified standards

4. Pharmacological Activities of Mangiferin



Fig.6: Multi-target pharmacological activities of Mangiferin.

The schematic illustrates the diverse therapeutic effects of mangiferin across oxidative stress, inflammation, metabolic disorders, neurodegeneration, cardiovascular dysfunction, and cancer-related pathways.

4.1 Antioxidant and Anti-inflammatory Effects

Mangiferin exhibits potent antioxidant properties primarily through reactive oxygen species (ROS) scavenging, which mitigates oxidative stress implicated in various pathological conditions. On a mechanistic level, it influences crucial signaling pathways, particularly the nuclear factor kappa B (NF-κB) pathway, thereby reducing the transcription of pro-inflammatory mediators. (Kannan et al., 2025) In vitro research highlights mangiferin's ability to mitigate oxidative damage and inhibit the production of inflammatory cytokines in cellular models.(Piao et al., 2020) Supporting in vivo studies confirm these results, indicating decreased markers of oxidative stress and inflammation in animal disease models, emphasizing its potential as a treatment for inflammatory disorders (Niu et al., 2012).

4.2Antidiabetic and Metabolic Effects

Mangiferin affects glucose metabolism and boosts insulin sensitivity through various mechanisms, such as activating AMP-activated protein kinase (AMPK) and altering glucose transporter expression. Preclinical models reveal that mangiferin administration improves glycemic control, reduces insulin resistance, and ameliorates metabolic dysfunctions associated with diabetes.(Li et al., 2018) Mechanistic insights suggest its role in regulating hepatic gluconeogenesis and lipid metabolism, contributing to its comprehensive metabolic benefits observed in diabetic animal models.

4.3 Anticancer Potential

The anticancer properties of mangiferin are mediated through the induction of cell cycle arrest and apoptosis in various cancer cell lines. It modulates critical signaling pathways such as PI3K/Akt and MAPK, which are involved in cell proliferation and survival. While in vitro studies provide robust evidence for its cytotoxic effects against tumor cells, in vivo data remain limited, and the translation of these findings to clinical relevance requires further investigation. The current evidence highlights both the promise and the need for more rigorous studies to elucidate its efficacy and safety profiles in oncology.(Bithi et al., 2025)

4.4 Neuroprotective and Cardioprotective Activities

Mangiferin exerts neuroprotective effects by mitigating neuroinflammation and oxidative stress, key contributors to neurodegenerative diseases. It modulates microglial activation and reduces neuronal damage in preclinical models, suggesting potential benefits in conditions such as Alzheimer’s and Parkinson’s disease. Cardioprotectively, mangiferin improves cardiovascular function by attenuating oxidative stress and inflammatory responses within the myocardium and vasculature. These effects contribute to the preservation of cardiac tissue integrity and function, highlighting its relevance in cardiovascular disease management.

5. TRANSLATIONAL ASPECTS OF MANGIFERIN

5.1. Pharmacokinetics and Bioavailability

Following oral administration, mangiferin is rapidly absorbed in the gastrointestinal tract, reaching peak plasma concentrations within 1 to 4 hours. This is succeeded by extensive phase II metabolism, primarily through glucuronidation and sulfation, facilitated by UDP-glucuronosyltransferase (UGT) enzymes. Its lipophilicity is moderate, allowing for effective distribution across various tissues. Mangiferin is predominantly excreted via the renal pathway, with a half-life ranging from 3 to 8 hours. Consequently, the pharmacokinetics of mangiferin are complex and may vary based on dosage and formulation (Lin, H.et al, 2020) Despite its potential therapeutic benefits, the efficacy of this treatment is significantly impeded by its limited absorption within the gastrointestinal tract. This limitation is primarily attributed to its high polarity, low solubility in water, and the body's propensity to expel it. These factors collectively hinder the intestinal permeability and serve as a protective mechanism for the

body. Consequently, there is a pressing need to develop more effective delivery methods, such as utilizing plant-based compounds or nanoparticles (Liu, Y.et al 2014).

Table 3: Mangiferin Pharmacokinetic Profile

PARAMETER	DESCRIPITION	KEY FINDINGS	REFERENCES
Absorption	Rapid GI uptake post-oral dose	T-max: 1-4 hours; nonlinear with dose	Lin, H., et al, 2020
Metabolism	Extensive phase II (glucuronidation/sulfation by UGT enzymes)	Primary metabolites in plasma/urine	Lin, H., at al, 2020
Distribution	Wide tissue distribution	Large V_d due to moderate lipophilicity	Liu, Y., et al 2014
Elimination	Predominantly renal	T1/2: 3-8 hours; low systemic clearance	Lin, H., et al 2020
Bioavailability	Severely limited (<2%) due to polarity, low solubility (0.1mg/mL) P-gp efflux	Requires phytosomes/nano-formulations	Zainuddin, R., et al 2025

5.2. Formulation Strategies

Nanocarriers, liposomes, and phospholipid complexes have significantly advanced the solubility and bioavailability of mangiferin for medical applications. Nanocarriers, such as NLCs and SPNMS, enhance stability by reducing particle size to less than 100 nanometers. This reduction facilitates controlled release and increases both the maximum concentration (Cmax) and overall exposure (AUC) by a factor of four (Khurana, R. K., et al. 2018; Barakat, S. et al, 2022). Liposomes, including transferosomes and glycethosomes, improve dermal absorption and provide protection against oxidative damage. Variants enriched with mangiferin demonstrate a ninefold enhancement in wound healing, achieving closure within 32 hours (Allaw, M., et al. 2020). Phospholipid complexes increase lipophilicity (enhancing oil-soluble solubility by 30-fold), facilitate membrane permeability, and offer hepatoprotective effects with a sustained release lasting up to 10 hours (Ma, H., et al. 2014; Bhattacharyya, A., et al. 2013). Collectively, these strategies ensure long-term physicochemical stability for up to six months and enhance efficacy across pharmacological endpoints (Al-Madhagi, H., et al. 2025).



Fig.7: Schematic representation of formulation and drug delivery strategies employed to overcome biopharmaceutical limitations of mangiferin.

Advanced delivery approaches such as nanoparticles, phytosomes, solid dispersions, liposomes, and co-crystals contribute to enhanced solubility, improved bioavailability, and superior therapeutic efficacy.

5.3. Safety and Toxicological Profile

The safety profile of mangiferin appears robust, with rodent studies indicating only transient adverse effects, such as respiratory distress and piloerection, at doses up to 2000 mg/kg. No dermal irritation was observed even at the highest dose, and the LD50 exceeds 2000 mg/kg, indicating low acute toxicity (Prado, M. A., et al 2014). Long-term studies, involving oral administration for 28 days at doses ranging from 250 to 1000 mg per kilogram of body weight daily, and a 90-day study at doses up to 2000 mg, revealed no adverse effects at the highest dose tested for a mango leaf extract containing 60% mangiferin. Furthermore, there were no indications of genotoxicity or organ-specific toxicity, except for transient pancreatic effects observed at high, but not prolonged, doses (Reddeman, R. A., et al 2019).

5.4. Clinical Evidence and Human Studies Clinical evidence for mangiferin remains limited, as no large-scale randomized controlled trials have been completed to date. However, a few small pilot studies and some human research suggest potential metabolic and cognitive benefits (Aslam, M., et al. 2024). A double-blind, placebo-controlled study found that Zynamite, a standardized mango leaf extract containing mangiferin, resulted in a rapid enhancement of cognitive performance and reduced mental fatigue. Additionally, observational data indicate that patients with type 2 diabetes receiving mangiferin-rich extracts exhibited improvements in insulin sensitivity and lipid profiles over a 12-week period (Imran, M., et al. 2024). Significant gaps persist between the strong preclinical efficacy observed in models of cancer, inflammation, and hepatotoxicity and their translation to humans. This discrepancy primarily arises from pharmacokinetic challenges, notably poor absorption (less than 2%), which prevents achieving the plasma concentrations effective in preclinical studies (10-100 mg/kg). Furthermore, issues such as variability in formulation, lack of pharmacokinetic studies, and absence of advanced clinical trials complicate the extrapolation of efficacy across species (Al-Madhagi, H., et al. 2025). **6. Future Perspectives**

The clinical application of mangiferin is contingent upon the establishment of robust analytical standards, such as HPLC-approved extraction techniques that achieve over 98% purity, alongside demonstrable health benefits to bridge the gap between laboratory potential and practical application. Despite the strong anti-inflammatory, antidiabetic, and anticancer effects observed in animal studies, the compound's low bioavailability and inconsistent extracts continue to impede its clinical utilization. Regulatory challenges for phytochemical therapeutics, including EMA/FDA requirements for well-characterized components, batch reproducibility, and evidence from phases I to III, further hinder progress. This issue is exacerbated by the lack of official drug guidelines and insufficient information on pharmacokinetics. There is a pressing need for standardized extraction methods for USP/EP-grade mangiferin, multicenter trials with clearly defined objectives, and its inclusion in pharmacopeia to ensure consistent production. Mangiferin, a multitarget xanthone, holds significant promise as a precursor for the development of semi-synthetic derivatives, similar to standardized berberine-based medications, and as a nutritional supplement supported by research suggesting potential benefits for metabolism and cognitive function.

7. Conclusion

Mangiferin emerges as a potent xanthone, supported by robust preclinical research demonstrating its anti-inflammatory, antidiabetic, anticancer, and neuroprotective properties. Its safety profile is exemplary, with a high safety margin (exceeding 2000 mg/kg) and a daily safe level of 2000 mg/kg. Furthermore, advanced formulation techniques enhance its bioavailability. However, challenges persist in translating these treatments to clinical practice due to limited oral bioavailability (less than 2% absorption), variability in plant-derived sources, and insufficient large-scale human studies. This underscores the necessity for standardized analytical methods, such as high-performance liquid chromatography (HPLC) protocols with purity exceeding 98% and adherence to official pharmacopeia guidelines, to ensure reproducibility. Standardization is crucial for bridging the gap between strong preclinical findings and clinical outcomes. Future research should prioritize multicenter randomized controlled trials, optimization of human pharmacokinetics and pharmacodynamics, and the establishment of regulatory pathways for phytopharmaceutical approval. As a versatile and safe phytochemical, enhanced by nanotechnology for delivery, mangiferin holds significant potential to advance translational phytomedicine, warranting urgent investment to fully realize its therapeutic benefits.

References

1. Abubakar, A. R., & Haque, M. (2020). Preparation of Medicinal Plants: Basic Extraction and Fractionation Procedures for Experimental Purposes. *Journal of Pharmacy & Bioallied Sciences*, *12*(1), 1–10. https://doi.org/10.4103/jpbs.jpbs_175_19

2. Akter, S., Moni, A., Faisal, G. M., Uddin, M. R., Jahan, N., Hannan, M. A., Rahman, A., & Uddin, M. J. (2022). Renoprotective Effects of Mangiferin: Pharmacological Advances and Future Perspectives. *International Journal of Environmental Research and Public Health*, *19*(3), 1864. https://doi.org/10.3390/ijerph19031864

3. Al-Madhagi, H. (2025). From Nature to Nanotechnology: The Bioactivities of Mangiferin Explored. *Nanotechnology, Science and Applications*, *18*, 277–294. https://doi.org/10.2147/nsa.s525423

4. Bithi, S. A., Al Hasan, M. S., Bhuia, M. S., Mia, E., Yana, N. T., Hasan, A. M. W., Uddin, M. B., Sayeed, M. A., Emon, Y., Hasan, R., Chowdhury, R., & Islam, M. T. (2025). Botanical sources, biopharmaceutical profile, anticancer effects with mechanistic insight, toxicological and clinical evidence of prunetin: a literature review. *Medical Oncology (Northwood, London, England)*, *42*(4). https://doi.org/10.1007/s12032-025-02646-z

5. Diarra, S. S. (2014). Potential of mango (Mangifera indica L.) seed kernel as a feed ingredient for poultry: a review. *World's Poultry Science Journal*, *70*(2), 279–288. https://doi.org/10.1017/s0043933914000294

6. El-Nashar, H. A. S., El-Labbad, E. M., Al-Azzawi, M. A., & Ashmawy, N. S. (2022). A New Xanthone Glycoside from Mangifera indica L.: Physicochemical Properties and In Vitro Anti-Skin Aging Activities. *Molecules*, *27*(9), 2609. https://doi.org/10.3390/molecules27092609

7. Etaware, P., America, O., Egara, O., & Ekun, V. (2025). Herbal Medicine: Scientific Validation and Future Prospects. *International Journal of Pharmacy and Chemistry*, *11*(3), 67–75. https://doi.org/10.11648/j.ijpc.20251103.12

8. Govindarajan, R., Tejas, V., & Pushpangadan, P. (2019). High-Performance Liquid Chromatography (HPLC) as a Tool for Standardization of Complex Herbal Drugs. *Journal of AOAC INTERNATIONAL*, *102*(4), 986–992. https://doi.org/10.5740/jaoacint.18-0378

9. Jangra, A., Arora, M. K., Kisku, A., & Sharma, S. (2020). The multifaceted role of mangiferin in health and diseases: a review. *Advances in Traditional Medicine*, *21*(4), 619–643. https://doi.org/10.1007/s13596-020-00471-5

10. Kannan, G., Paul, B. M., & Thangaraj, P. (2025). Stimulation, regulation, and inflammaging interventions of natural compounds on nuclear factor kappa B (NF-kB) pathway: a comprehensive review. *Inflammopharmacology*, *33*(1), 145–162. https://doi.org/10.1007/s10787-024-01635-4

11. Kumar, M., Saurabh, V., Tomar, M., Hasan, M., Changan, S., Sasi, M., Maheshwari, C., Prajapati, U., Singh, S., Prajapat, R. K., Dhumal, S., Punia, S., Amarowicz, R., & Mekhemar, M. (2021). Mango (Mangifera indica L.) Leaves: Nutritional Composition, Phytochemical Profile, and Health-Promoting Bioactivities. *Antioxidants*, *10*(2), 299. https://doi.org/10.3390/antiox10020299

12. Li, J., Liu, M., Yu, H., Wang, W., Han, L., Chen, Q., Ruan, J., Wen, S., Zhang, Y., & Wang, T. (2018). Mangiferin Improves Hepatic Lipid Metabolism Mainly Through Its Metabolite-Norathyriol by Modulating SIRT-1/AMPK/SREBP-1c Signaling. *Frontiers in Pharmacology*, *9*(24). https://doi.org/10.3389/fphar.2018.00201

13. Liu, M., Liu, Y., Ge, Y., Zhong, Z., Wang, Z., Wu, T., Zhao, X., & Zu, Y. (2020). Solubility, Antioxidation, and Oral Bioavailability Improvement of Mangiferin Microparticles Prepared Using the Supercritical Antisolvent Method. *Pharmaceutics*, *12*(2), 90. https://doi.org/10.3390/pharmaceutics12020090

14. Mei, S., Perumal, M., Battino, M., Kitts, D. D., Xiao, J., Ma, H., & Chen, X. (2021). Mangiferin: a review of dietary sources, absorption, metabolism, bioavailability, and safety. *Critical Reviews in Food Science and Nutrition*, *63*(18), 3046–3064. https://doi.org/10.1080/10408398.2021.1983767

15. Morozkina, S. N., Nhung Vu, T. H., Generalova, Y. E., Snetkov, P. P., & Uspenskaya, M. V. (2021). Mangiferin as New Potential Anti-Cancer Agent and Mangiferin-Integrated Polymer Systems—A Novel Research Direction. *Biomolecules*, *11*(1), 79. https://doi.org/10.3390/biom11010079

16. Niu, Y., Li, S., Na, L., Feng, R., Liu, L., Li, Y., & Sun, C. (2012). Mangiferin Decreases Plasma Free Fatty Acids through Promoting Its Catabolism in Liver by Activation of AMPK. *PLoS ONE*, *7*(1), e30782. https://doi.org/10.1371/journal.pone.0030782

17. Piao, C. H., Fan, Y. J., Nguyen, T. V., Song, C. H., & Chai, O. H. (2020). Mangiferin Alleviates Ovalbumin-Induced Allergic Rhinitis via Nrf2/HO-1/NF-κB Signaling Pathways. *International Journal of Molecular Sciences*, *21*(10), 3415. https://doi.org/10.3390/ijms21103415

18. Pierre, A., Favory, R., Lancel, S., & Preau, S. (2025). Can patient-derived in vitro models improve clinical translation in critical care research when used before animal studies? *Intensive Care Medicine Experimental*, *13*(1). https://doi.org/10.1186/s40635-025-00814-z

19. Rossouw, G. C., Orr, R., Bennett, D., & Bally, I. S. E. (2024). The roles of non-structural carbohydrates in fruiting: a review focusing on mango (Mangifera indica). *Functional Plant Biology*, *51*(4). https://doi.org/10.1071/fp23195

20. Sun, S., Yu, Y., Jo, Y., Han, J. H., Xue, Y., Cho, M., Bae, S.-J., Ryu, D., Park, W., Ha, K.-T., & Zhuang, S. (2025). Impact of extraction techniques on phytochemical composition and bioactivity of natural product mixtures. *Frontiers in Pharmacology*, *16*. https://doi.org/10.3389/fphar.2025.1615338

21. Tao, B., Li, X., Hao, M., Tian, T., Li, Y., Li, X., Yang, C., Li, Q., Feng, Q., Zhou, H., Zhao, Y., Wang, D., & Liu, W. (2025). Organoid-Guided Precision Medicine: From Bench to Bedside. *MedComm*, *6*(5). https://doi.org/10.1002/mco2.70195

22. Tegl, G., & Nidetzky, B. (2020). Leloir glycosyltransferases of natural product C-glycosylation: structure, mechanism and specificity. *Biochemical Society Transactions*, *48*(4), 1583–1598. https://doi.org/10.1042/bst20191140

23. Vishwakarma, K. K., Hafeez, A., Usmani, S. A., Noor, L., & Khan, I. R. (2025). Nanocarrier-Based Delivery Approaches of Mangiferin: An Updated Review on Leveraging Biopharmaceutical Characteristics of the Bioactive. *Current Pharmaceutical Biotechnology*, *26*(14), 2270–2287. https://doi.org/10.2174/0113892010318524240907135527

24. Wang, M., Liang, Y., Chen, K., Wang, M., Long, X., Liu, H., Sun, Y., & He, B. (2022). The management of diabetes mellitus by mangiferin: advances and prospects. *Nanoscale*, *14*(6), 2119–2135. https://doi.org/10.1039/d1nr06690k

25. Wu, J.-Y., Ding, H.-Y., Wang, T.-Y., Tsai, Y.-L., Ting, H.-J., & Chang, T.-S. (2021). Improving Aqueous Solubility of Natural Antioxidant Mangiferin through Glycosylation by Maltogenic Amylase from Parageobacillus galactosidasius DSM 18751. *Antioxidants*, *10*(11), 1817. https://doi.org/10.3390/antiox10111817

26. Zhao, Q., Zhang, C., Zhang, W., Zhang, S., Liu, Q., & Guo, Y. (2025). Applications and challenges of biomarker-based predictive models in proactive health management. *Frontiers in Public Health*, *13*. https://doi.org/10.3389/fpubh.2025.1633487

27. Zivković, J., Kumar, K. A., Rushendran, R., Ilango, K., Fahmy, N. M., El-Nashar, H. A. S., El-Shazly, M., Ezzat, S. M., Melgar-Lalanne, G., Romero-Montero, A., Peña-Corona, S. I., Leyva-Gomez, G., Sharifi-Rad, J., & Calina, D. (2023). Pharmacological properties of mangiferin: bioavailability, mechanisms of action and clinical perspectives. *Naunyn-Schmiedeberg's Archives of Pharmacology*, *397*(2), 763–781. https://doi.org/10.1007/s00210-023-02682-4

28. Lin, H., Teng, H., Wu, W., Li, Y., Lv, G., Huang, X., Yan, W., & Lin, Z. (2020). Pharmacokinetic and metabolomic analyses of mangiferin calcium salt in rat models of type 2 diabetes and non-alcoholic fatty liver disease. BMC Pharmacology & Toxicology, 21(1), Article 59. https://doi.org/10.1186/s40360-020-00438-x.

29. Liu, Y., Xu, J., Chen, X., Wang, X., & Liu, Q. (2014). Comparative pharmacokinetic study of mangiferin after oral administration of monomer and extract from Anemarrhena asphodeloides. Journal of Pharmaceutical and Biomedical Analysis, 109, 33-39. https://doi.org/10.1016/j.jpba.2014.12.032.
30. Khurana, R. K., et al. (2018). Improving the biopharmaceutical attributes of mangiferin using vitamin E-TPGS co-loaded self-assembled phospholipidic nano-mixed micellar systems. Drug Delivery and Translational Research, 8(3), 617–632. https://doi.org/10.1007/s13346-018-0498-4.

31. Barakat, S., Nasr, M., Ahmed, R. F., Badawy, S., & Mortada, N. (2022). Recent formulation advances of mangiferin. Revista Brasileira de Farmacognosia, 32, 871–882. https://doi.org/10.1007/s43450-022-00297-z.

32. Allaw, M., et al. (2020). Nanovesicles for the topical delivery of mangiferin: Design, characterization, and in vitro/in vivo evaluation. Pharmaceutics, 12(12), 1222.

33. Ma, H., et al. (2014). Improving permeability and oral absorption of mangiferin by phospholipid complexation. Archives of Pharmacal Research, 37(8), 1023–1030.

34. Bhattacharyya, A., et al. (2013). Soya phospholipid complex of mangiferin enhances its hepatoprotectivity by improving its bioavailability and pharmacokinetics. Journal of the Science of Food and Agriculture, 94(7), 1381–1388.

35. Al-Madhagi, H., et al. (2025). From nature to nanotechnology: The bioactivities of mangiferin explored. Nanotechnology, Science and Applications. https://doi.org/10.2147/NSA.S.

36. Prado, M. A., Marques, F. D. S., Bolanos, L. A. C., Pereira, C. B., & Oliveira, R. B. (2014). Acute and 28-day subchronic toxicity studies of mangiferin, a glucosylxanthone isolated from Mangifera indica L. stem bark. Journal of Pharmacy & Pharmaceutical Sciences, 3(1), 13-23. https://jppres.com/jppres/mangiferin-toxicity-studies.

37. Reddeman, R. A., Glávits, R., Endres, J. R., Clewell, A. E., Hirka, G., Vértesi, A., Béres, E., Pasics Szakonyiné, I., & Szakonyi, G. (2019). A toxicological evaluation of mango leaf extract (Mangifera indica)

containing 60% mangiferin. Journal of Toxicology, 2019, Article 4763015. https://doi.org/10.1155/2019/4763015.

38. Aslam, M., et al. (2024). Acute effects of mango leaf extract on cognitive function in healthy adults: A randomized, double-blind, placebo-controlled trial. Frontiers in Nutrition, 11, 1298807. https://doi.org/10.3389/fnut.2024.1298807.

39. Imran, M., et al. (2024). Pharmacological properties of mangiferin: Bioavailability, mechanisms of action and clinical perspectives. Food and Chemical Toxicology. https://pubmed.ncbi.nlm.nih.gov/37658210.